Update on CFO Appointment

RNS Number : 3503Q

Genedrive PLC

29 November 2016

 

For release: 29 November 2016

genedrive plc ("genedrive" or the "Company")

Update on CFO Appointment

genedrive plc (LSE: GDR), the near patient molecular diagnostics company, is pleased to announce that, following his appointment as Chief Financial Officer and a Director of the Company as announced on 21 September 2016, Matthew Fowler will join genedrive plc on 13 December 2016.

Matthew joins genedrive plc with over 15 years of experience in senior positions in the manufacturing, power and support services industries. Prior to joining genedrive plc, Matthew spent eight years as Group Financial Controller of Scapa Group plc, a multinational manufacturing AIM-quoted business. At Scapa Group plc, Matthew was responsible for shaping and managing finance within the Group as well as strategy development and other core processes.

Before joining Scapa Group plc, Matthew spent three years at British Nuclear Group as Finance Manager where he managed the corporate centre's finance team and was responsible for planning, reporting and accounting. Matthew trained and qualified in the audit department of Deloitte & Touche.

- Ends -

For further details please contact:

genedrive plc

David Budd: CEO                                                                                                              [phone]

Peel Hunt LLP

James Steel                                                                                                                       [phone]

Oliver Jackson

Consilium Strategic Communications

Chris Gardner                                                                                                                    [phone]

Matthew Neal

Laura Thornton

[e-mail] 

Notes to Editors

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® platform and MTB/RIF test have been launched in India and a Genedrive® HCV test has been successfully assessed by the Institut Pasteur, Paris.

genedrive plc was formerly Epistem plc and continues to provide contract research services to drug development companies under the Epistem brand name.

Further details can be found at: www.genedriveplc.com and www.genedrive.com 

 

END

 

 

BOAPGGGUGUPQGMR